Downregulation of tNASP inhibits proliferation through regulating cell cycle-related proteins and inactive ERK/MAPK signal pathway in renal cell carcinoma cells

Tumor Biology

Volumn 36, Issue 7, 2015, Pages 5209-5214

  Fang, Jianzheng ^a   Wang, Hainan ^a   Xi, Wei ^a   Cheng, Gong ^a   Wang, Shangqian ^a   Su, Shifeng ^a   Zhang, Shengli ^a   Deng, Yunfei ^a   Song, Zhen ^a   Xu, Aiming ^a   Liu, Bianjiang ^a   Cao, Jingyi ^b   Wang, Zengjun ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b The Second People's Hospital of Xuzhou   (China)

Author keywords

ERK MAPK; Proliferation; Renal cell carcinoma; tNASP

Indexed keywords

CHAPERONE; CYCLIN D1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P21; SMALL INTERFERING RNA; TESTICULAR NUCLEAR AUTO ANTIGENIC SPERM PROTEIN; UNCLASSIFIED DRUG; AUTOANTIGEN; CELL CYCLE PROTEIN; NASP PROTEIN, HUMAN; NUCLEAR PROTEIN; P21 ACTIVATED KINASE; PAK2 PROTEIN, HUMAN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; G1 PHASE CELL CYCLE CHECKPOINT; GENE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RENAL CELL CARCINOMA CELL LINE; SIGNAL TRANSDUCTION; TNASP GENE; UPREGULATION; BIOSYNTHESIS; CELL CYCLE CHECKPOINT; CELL CYCLE G1 PHASE; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; TUMOR CELL LINE;

AUTOANTIGENS; CARCINOMA, RENAL CELL; CELL CYCLE CHECKPOINTS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE SIGNALING SYSTEM; NUCLEAR PROTEINS; P21-ACTIVATED KINASES; RNA, SMALL INTERFERING;

EID: 84938198126     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3177-9     Document Type: Article

References (21)

1. Chow WH, Devesa SS, Warren JL, Fraumeni Jr JF. Rising incidence of renal cell cancer in the United States. JAMA. 1999;281(17):1628–31.
2. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008;34(3):193–205.
3. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. Cancer. 2007;109(9):1763–8.
4. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373(9669):1119–32.
5. Jiang Z, Chu PG, Woda BA, Liu Q, Balaji KC, et al. Combination of quantitative IMP3 and tumor stage: a new system to predict metastasis for patients with localized renal cell carcinomas. Clin Cancer Res. 2008;14(17):5579–84.
6. Finn RM, Browne K, Hodgson KC, Ausió J. sNASP, a histone H1-specific eukaryotic chaperone dimer that facilitates chromatin assembly. Biophys J. 2008;95(3):1314–25.
7. Richardson RT, Batova IN, Widgren EE, Zheng LX, Whitfield M, et al. Characterization of the histone H1-binding protein, NASP, as a cell cycle-regulated somatic protein. J Biol Chem. 2000;275(39):30378–86.
8. Tagami H, Ray-Gallet D, Almouzni G, Nakatani Y. Histone H3.1 and H3.3 complexes mediate nucleosome assembly pathways dependent or independent of DNA synthesis. Cell. 2004;116(1):51–61.
9. Wang H, Walsh ST, Parthun MR. Expanded binding specificity of the human histone chaperone NASP. Nucleic Acids Res. 2008;36(18):5763–72.
10. Alekseev OM, Richardson RT, Alekseev O, O'Rand MG. Analysis of gene expression profiles in HeLa cells in response to overexpression or siRNA-mediated depletion of NASP. Reprod Biol Endocrinol. 2009;7:45.
11. Richardson RT, Alekseev OM, Grossman G, Widgren EE, Thresher R, et al. Nuclear autoantigenic sperm protein (NASP), a linker histone chaperone that is required for cell proliferation. J Biol Chem. 2006;281(30):21526–34.
12. Chatterjee M, Mohapatra S, Ionan A, Bawa G, Ali-Fehmi R, et al. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res. 2006;66(2):1181–90.
13. Amundson SA, Do KT, Vinikoor LC, Lee RA, Koch-Paiz CA, et al. Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen. Cancer Res. 2008;68(2):415–24.
14. Martin KJ, Patrick DR, Bissell MJ, Fournier MV. Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets. PLoS One. 2008;3(8):e2994.
15. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530–6.
16. Alekseev OM, Richardson RT, Tsuruta JK, O'Rand MG. Depletion of the histone chaperone tNASP inhibits proliferation and induces apoptosis in prostate cancer PC-3 cells. Reprod Biol Endocrinol. 2011;9(1):50.
17. Tashiro E, Tsuchiya A, Imoto M. Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression. Cancer Sci. 2007;98(5):629–35.
18. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9(3):153–66.
19. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110(6):673–87.
20. Lam JS, Breda A, Belldegrun AS, Figlin RA. Evolving principles of surgical management and prognostic factors for outcome in renal cell carcinoma. J Clin Oncol. 2006;24(35):5565–75.
21. Rini BI. Metastatic renal cell carcinoma: many treatment options, one patient. J Clin Oncol. 2009;27(19):3225–34.